DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Exercise and Metformin in Colorectal and Breast Cancer Survivors

Phase 2

Completed

Conditions: Breast Cancer
Colorectal Cancer

Interventions: Other: Educational information
Behavioral: Exercise training
Drug: Metformin

First Posted Date: 2011-04-22

Last Posted Date: 2018-06-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 139

Registration Number: NCT01340300

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndrome
Lymphoma

Interventions: Drug: Bortezomib
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2011-03-28

Last Posted Date: 2017-05-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT01323920

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate

Completed

Conditions: CNS Lymphoma
CNS Involvement of Systemic Lymphoma

First Posted Date: 2011-03-21

Last Posted Date: 2019-01-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT01319591

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Amgen 386 for Recurrent Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: Amgen 386
Drug: Bevacizumab

First Posted Date: 2011-02-04

Last Posted Date: 2017-07-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT01290263

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Early Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Eltrombopag

First Posted Date: 2011-01-31

Last Posted Date: 2019-03-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT01286675

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Hydroxychloroquine

First Posted Date: 2011-01-11

Last Posted Date: 2017-06-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01273805

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer
Lung Cancer
SCLC

Interventions: Drug: Pazopanib

First Posted Date: 2010-12-03

Last Posted Date: 2019-04-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT01253369

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

MK-2206 for Recurrent Malignant Glioma

Phase 2

Withdrawn

Conditions: Malignant Glioma

Interventions: Drug: MK-2206

First Posted Date: 2010-11-29

Last Posted Date: 2016-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01249105

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States

and more 2 locations

FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer

Not Applicable

Completed

Conditions: Esophageal Cancer

Interventions: Drug: 3'-deoxy-3'-(18) F-fluorothymidine

First Posted Date: 2010-11-18

Last Posted Date: 2017-05-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01243619

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Phase 2

Terminated

Conditions: Chronic Graft-versus-host Disease

Interventions: Drug: Alefacept

First Posted Date: 2010-10-22

Last Posted Date: 2013-08-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT01226420

Locations: 🇺🇸
Fred Hutch Cancer Research Center, Seattle, Washington, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy